Eton Pharmaceuticals, Inc. Files Definitive Proxy Statement (DEF 14A)

TL;DR

<b>Eton Pharmaceuticals, Inc. has filed its Definitive Proxy Statement (DEF 14A) detailing executive compensation and corporate governance matters.</b>

AI Summary

Eton Pharmaceuticals, Inc. (ETON) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Eton Pharmaceuticals, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 26, 2024. The filing covers the fiscal year ending December 31, 2023. The company's principal executive offices are located at 21925 W. Field Parkway, Suite 235, Deer Park, IL 60010. The filing includes information related to equity awards and their adjustments for the fiscal years 2022 and 2023. The company is incorporated in Delaware.

Why It Matters

For investors and stakeholders tracking Eton Pharmaceuticals, Inc., this filing contains several important signals. This filing is crucial for shareholders to understand executive compensation structures and make informed voting decisions at the upcoming shareholder meeting. The DEF 14A provides detailed disclosures on equity awards, changes in their value, and vesting schedules, which are key components of executive remuneration.

Risk Assessment

Risk Level: low — Eton Pharmaceuticals, Inc. shows low risk based on this filing. The filing is a routine DEF 14A, which is standard for public companies and does not contain immediate material news or significant financial shifts.

Analyst Insight

Shareholders should review the executive compensation details and any proposed resolutions to prepare for the upcoming shareholder meeting.

Key Numbers

• 2023-12-31 — Fiscal Year End (Fiscal Year End Date)
• 2024-04-26 — Filing Date (Date Filed)
• 20240611 — Period of Report (Reporting Period)

Key Players & Entities

• Eton Pharmaceuticals, Inc. (company) — Registrant
• 2024-04-26 (date) — Filing Date
• 20240611 (date) — Period of Report
• 0001710340 (company) — Central Index Key
• DE (jurisdiction) — State of Incorporation
• IL (state) — Business Address State
• 60010 (zip_code) — Business Address Zip
• 2834 (sic_code) — Standard Industrial Classification

FAQ

Industry Context

Eton Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on developing and commercializing specialty pharmaceutical products.

Regulatory Implications

As a publicly traded company, Eton Pharmaceuticals is subject to SEC regulations, including the requirement to file proxy statements (DEF 14A) for shareholder meetings.

What Investors Should Do

1. Review the executive compensation disclosures within the DEF 14A.
2. Understand the proposals to be voted on at the shareholder meeting.
3. Assess any changes in corporate governance practices outlined in the filing.

Key Dates

• 2024-04-26: Filing of DEF 14A — Official filing of the proxy statement by Eton Pharmaceuticals, Inc.

Year-Over-Year Comparison

This is the initial filing of the DEF 14A for the current reporting period, with no prior filing data available for direct comparison within this document.

Filing Documents

• eton20240318_def14a.htm (DEF 14A) — 487KB
• bodchartimage2024.jpg (GRAPHIC) — 22KB
• image01.jpg (GRAPHIC) — 2KB
• image04.jpg (GRAPHIC) — 29KB
• image05.jpg (GRAPHIC) — 44KB
• image06.jpg (GRAPHIC) — 86KB
• image07.jpg (GRAPHIC) — 56KB
• image08.jpg (GRAPHIC) — 50KB
• 0001437749-24-013429.txt (&nbsp;) — 1606KB
• eton-20231231.xsd (EX-101.SCH) — 3KB
• eton-20231231_def.xml (EX-101.DEF) — 2KB
• eton-20231231_lab.xml (EX-101.LAB) — 2KB
• eton-20231231_pre.xml (EX-101.PRE) — 1KB
• eton20240318_def14a_htm.xml (XML) — 49KB

Executive Compensation

Executive Compensation 19 Report of the Compensation Committee of the Board of Directors 26

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 26 Section 16(A) Beneficial Ownership Reporting Compliance 27 Related Party Transactions 27 Transaction of Other Business 27 Proposal Four - Ratification of the Appointment of Our Independent Registered Public Accounting Firm 28 Report of the Audit Committee of the Board of Directors 29 Additional Information 30 3 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 11, 2024 GENERAL INFORMATION This Proxy Statement and related materials are available to you on the Internet, or at your request we have delivered printed versions to you by mail, in connection with the board of directors' solicitation of proxies for our 2024 Annual Meeting of Stockholders (the " Annual Meeting "), and any adjournment of the Annual Meeting. If you requested printed versions of these materials by mail, they will also include a proxy card for the Annual Meeting. The Annual Meeting will be held at 10:00 a.m. CDT virtually at www.virtualshareholdermeeting.com/ETON2024. This Proxy Statement is being made available to stockholders beginning on or about April 26, 2024. Pursuant to rules adopted by the Securities and Exchange Commission (" SEC "), we are providing access to our proxy materials over the Internet. Accordingly, we are sending a Notice of Internet Availability of Proxy Materials (the " Notice ") to our stockholders of record and beneficial owners as of the record date identified below. The mailing of the Notice to our stockholders is scheduled to begin on or about May 1, 2024. IMPORTANT NOTICE REGARDING THE INTERNET AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL STOCKHOLDERS MEETING TO BE HELD ON JUNE 11, 2024: This proxy statement, the accompanying proxy card or voting instruction card and our 2023 Annual Report on Form 10-K are available at www.proxyvote.com . In this Proxy Statement the terms "Eton," the "Company," "we," "us," and "our" refer to Eton Ph

View Full Filing

View this DEF 14A filing on SEC EDGAR